Article Figures & Data
Figures
- FIGURE 1.
Twenty-year actuarial Kaplan–Meier PCa-specific survival probability curve in whole sample. Numbers indicate patients at risk at time tn and number of PCa-specific deaths occurred between tn and tn + 2.
- FIGURE 2.
Kaplan–Meier PCa-specific survival probability curves in patients with negative 11C-choline PET/CT and in patients with positive 11C-choline PET/CT. Numbers indicate patients at risk at time tn and number of PCa-specific deaths occurred between tn and tn + 2.
- FIGURE 3.
Kaplan–Meier PCa-specific survival probability curves in patients with negative 11C-choline PET/CT (PET/CT−), in patients with 11C-choline PET/CT suggestive of local recurrence or lymph node disease (PET/CT+ LR/Lfn), and in patients with 11C-choline PET/CT suggestive of bone metastases (PET/CT+ bone). Numbers indicate patients at risk at time tn and number of PCa-specific deaths occurred between tn and tn + 2.
- FIGURE 4.
Nomogram (A) and calibration factor (B) predicting 10-y PCa-specific survival probability (calculated from radical prostatectomy). Perfect prediction would correspond to diagonal 45° broken line. Dotted line indicates actual nomogram performance. Expected performance on future data is represented through solid line.
- FIGURE 5.
Nomogram (A) and calibration factor (B) predicting 15-y PCa-specific survival probability (calculated from radical prostatectomy).
- FIGURE 6.
Nomogram (A) and calibration factor (B) predicting 5-y PCa-specific survival probability (calculated from 11C-choline PET/CT).
Tables
Parameter Whole sample (n = 195) PET/CT negative (n = 83) PET/CT positive (n = 112) P Interval prostatectomy—11C-choline PET/CT (y) 0.350 Mean ± SD 4.8 ± 3.0 4.5 ± 2.7 4.9 ± 3.2 Median 4.2 4.2 4.1 Range 0.4–14.4 0.4–12.4 0.7–14.4 Age (y) 0.864 Mean ± SD 68 ± 7 68 ± 6 68 ± 7 Median 68 68 67 Range 50–85 50–79 51–85 PSA (ng/mL) <0.001 Mean ± SD 5.17 ± 8.45 2.60 ± 5.39 7.08 ± 9.73 Median 1.82 1.01 3.03 Range 0.22–48.6 0.22–35.0 0.25–48.6 PSADT (mo) (n = 76) 0.003 Mean ± SD 6.67 ± 4.82 9.04 ± 5.68 5.23 ± 3.58 Median 5.47 7.89 4.79 Range 1.11–23.59 1.13–23.59 1.11–18.37 Pathologic stage <0.001 pT2pN0 62 (32) 41 (49) 21 (19) pT3pN0 and pT4pN0 82 (42) 28 (34) 54 (48) Any T pN1 51 (26) 14 (17) 37 (33) Gleason score 0.411 <7 40 (20) 20 (24) 20 (18) 7 85 (44) 37 (45) 48 (43) >7 70 (36) 26 (31) 44 (39) Data in parentheses are percentages.
Survival (y) PET/CT negative (n = 83) PET/CT positive (n = 112) 5 97.5% (95.8%–99.2%) 81.8% (78.1%–85.5%) 10 80.9% (76.0%–85.8%) 55.0% (49.6%–60.4%) 15 53.7% (41.6%–65.8%) 17.8% (11.5%–24.1%) Data in parentheses are 95% CI.
- TABLE 3
Cox Regression Analysis of Factors Predicting PCa-Specific Survival in Whole Sample (n = 195)
Univariate analysis Multivariate analysis Parameter HR P HR P 11C-choline PET/CT 3.02 (1.80–5.08) <0.001 2.53 (1.41–4.53) 0.002 Age (y) 1.00 (0.97–1.04) 0.738 1.01 (0.98–1.05) 0.469 PSA (ng/mL) 1.04 (1.02–1.06) 0.001 1.03 (1.00–1.05) 0.037 Pathologic stage 0.007 0.065 pT2pN0 1 (reference) 1 (reference) pT3pN0 and pT4pN0 1.24 (0.70–2.17) 0.458 0.79 (0.42–1.46) 0.453 Any T pN1 2.33 (1.32–4.09) 0.003 1.48 (0.82–2.69) 0.191 Gleason score 0.001 0.025 <7 1 (reference) 1 (reference) 7 1.81 (0.95–3.45) 0.069 1.57 (0.81–3.04) 0.176 >7 3.26 (1.68–6.35) <0.001 2.49 (1.25–4.95) 0.009 Additional therapy 1.83 (1.17–2.86) 0.008 1.20 (0.73–1.97) 0.451 Data in parentheses are 95% CI.
- TABLE 4
Cox Regression Analysis of Factors Predicting PCa-Specific Survival in Patients with PSADT (n = 76)
Univariate analysis Bivariate analysis Parameter HR P HR P 11C-choline PET/CT 3.83 (1.48–9.92) 0.006 2.75 (1.04–7.32) 0.042 PSADT (mo) 0.86 (0.77–0.95) 0.004 0.88 (0.79–0.98) 0.029 Data in parentheses are 95% CI.
- TABLE 5
PCa-Specific Survival Probabilities (%) in Patients With Pathologic 11C-Choline Uptake and in Patients Without (M0) and With (M1) Distant Metastases
PET/CT positive Survival (y) Prostatic bed/lymph nodes (n = 63)* Skeleton (n = 49) M0, prostatic bed/pelvic lymph nodes (n = 46)† M1, retroperitoneal lymph nodes/skeleton (n = 66)† 5 92.6% (89.3%–95.9%) 65.9% (59.0%–72.8%) 97.8% (95.6%–1.00%) 69.6% (63.9%–75.3%) 10 61.2% (54.1%–68.3%) 47.1% (39.0%–55.2%) 75.5% (68.1%–82.9%) 55.0% (47.9%–62.1%) 15 20.4% (10.2%–30.6%) 5.6% (0.3%–10.9%) 25.0% (12.5%–37.5%) 4.7% (0.2%–9.2%) - TABLE 6
Cox Regression Analysis of Factors Predicting PCa-Specific Survival (Calculated from Time of 11C-Choline PET/CT) in Whole Sample (n = 195)
Univariate analysis Multivariate analysis Parameter HR P HR P 11C-choline PET/CT 4.03 (2.37–6.87) <0.001 3.16 (1.72–5.78) <0.001 Age (y) 1.04 (1.00–1.07) 0.045 1.06 (1.02–1.10) 0.002 PSA (ng/mL) 1.05 (1.02–1.07) <0.001 1.05 (1.02–1.07) <0.001 Pathologic stage 0.005 0.017 pT2pN0 1 (reference) 1 (reference) pT3pN0 and pT4pN0 1.22 (0.69–2.14) 0.485 0.89 (0.49–1.64) 0.727 Any T pN1 2.38 (1.35–4.19) 0.003 1.85 (1.02–3.38) 0.043 Gleason score 0.276 0.610 <7 1 (reference) 1 (reference) 7 1.29 (0.69–2.42) 0.415 1.11 (0.58–2.12) 0.732 >7 1.65 (0.87–3.11) 0.119 1.35 (0.70–2.60) 0.366 Additional therapy 2.01 (1.28–3.15) 0.002 1.15 (0.69–1.91) 0.576 Data in parentheses are 95% CI.
- TABLE 7
Cox Regression Analysis of Factors Predicting PCa-Specific Survival (Calculated from Time of 11C-Choline PET/CT) in Patients with PSADT (n = 76)
Univariate analysis Bivariate analysis Parameter HR P HR P 11C-choline PET/CT 5.61 (2.16–14.53) <0.001 4.51 (1.68–12.11) 0.003 PSADT (mo) 0.88 (0.80–0.97) 0.012 0.93 (0.84–1.03) 0.178 Data in parentheses are 95% CI.
Jump to section
Related Articles
Cited By...
- Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis
- What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer
- Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes?
- Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging 11C-Choline PET/CT Scan Before Salvage Radiation Therapy?